CAJ | 학술논문

背景:头颈部肿瘤与遗传因素密切相关,但其一级亲属是否为肿瘤高风险人群?中药五加皮有抗突变的染色体稳定剂,能否提高一级亲属的抗癌能力?目的:探讨头颈部肿瘤的遗传因素及五加皮对其染色体的稳定作用.设计:以人外周血为对象的对照实验.单位:吉林大学基础医学院医学遗传学教研室及第一医院耳鼻咽喉科,英国华威(沃瑞克)大学.对象:对象来源时间为2001-10/2002-03.头颈肿瘤患者及其一级亲属均来自吉林大学第一医院耳鼻喉科,健康人群来自长春市中心血站健康献血者.实验对象共110例,分为3组.①对照组50例,男25例,女25例;来自健康献血者;均无癌家族史,身体健康,无癌症和病史.②患者组30例,男22例,女8例;喉癌20例,鼻咽癌10例;未经放射治疗及抗肿瘤药物治疗.③一级亲属组30例,男19例,女11例;为喉癌、鼻咽癌患者的一级亲属;除有癌家族史外,身体健康.以上参与者均知情同意.方法:采集实验对象外周血,进行淋巴细胞培养,培养周期为72 h,在67 h时加入致诱变剂博来霉素(15 mg/L),抗诱变实验加入博来霉素的同时加入五加皮(800mg/L).继续培养72 h收获细胞,常规方法制片,吉姆萨不显带染色.选择分散好的分裂相,观察染色体的断裂情况.计算平均每细胞染色单体断裂率(即等于本组中所有染色单体断裂的总和除以所有观察的细胞总数).主要观察指标:每细胞染色单体断裂率.结果:患者3组110例进入结果分析.①应用博来霉素所致的每细胞染色单体断裂率:对照组明显低于患者组及一级亲属组(0.16±0.06,0.48±0.14,0.42±0.12,P＜0.01),但患者组及一级亲属组比较无差异(P＞0.05).②应用五加皮和博来霉素后与单纯应用博来霉素所致每细胞染色单体断裂率的比较:患者组及一级亲属组均显著降低(0.48±0.14,0.15±0.08,0.42±0 12,0.17±0.11,P＜0 01).结论:头颈部肿瘤患者的一级亲属应列为肿瘤易患高风险人群,加入五加皮发挥了染色体稳定剂的作用,对博来霉素所致的患者及一级亲属每细胞染色单体断裂率有明显的抑制作用. 揹景:頭頸部腫瘤與遺傳因素密切相關,但其一級親屬是否為腫瘤高風險人群?中藥五加皮有抗突變的染色體穩定劑,能否提高一級親屬的抗癌能力?目的:探討頭頸部腫瘤的遺傳因素及五加皮對其染色體的穩定作用.設計:以人外週血為對象的對照實驗.單位:吉林大學基礎醫學院醫學遺傳學教研室及第一醫院耳鼻嚥喉科,英國華威(沃瑞剋)大學.對象:對象來源時間為2001-10/2002-03.頭頸腫瘤患者及其一級親屬均來自吉林大學第一醫院耳鼻喉科,健康人群來自長春市中心血站健康獻血者.實驗對象共110例,分為3組.①對照組50例,男25例,女25例;來自健康獻血者;均無癌傢族史,身體健康,無癌癥和病史.②患者組30例,男22例,女8例;喉癌20例,鼻嚥癌10例;未經放射治療及抗腫瘤藥物治療.③一級親屬組30例,男19例,女11例;為喉癌、鼻嚥癌患者的一級親屬;除有癌傢族史外,身體健康.以上參與者均知情同意.方法:採集實驗對象外週血,進行淋巴細胞培養,培養週期為72 h,在67 h時加入緻誘變劑博來黴素(15 mg/L),抗誘變實驗加入博來黴素的同時加入五加皮(800mg/L).繼續培養72 h收穫細胞,常規方法製片,吉姆薩不顯帶染色.選擇分散好的分裂相,觀察染色體的斷裂情況.計算平均每細胞染色單體斷裂率(即等于本組中所有染色單體斷裂的總和除以所有觀察的細胞總數).主要觀察指標:每細胞染色單體斷裂率.結果:患者3組110例進入結果分析.①應用博來黴素所緻的每細胞染色單體斷裂率:對照組明顯低于患者組及一級親屬組(0.16±0.06,0.48±0.14,0.42±0.12,P＜0.01),但患者組及一級親屬組比較無差異(P＞0.05).②應用五加皮和博來黴素後與單純應用博來黴素所緻每細胞染色單體斷裂率的比較:患者組及一級親屬組均顯著降低(0.48±0.14,0.15±0.08,0.42±0 12,0.17±0.11,P＜0 01).結論:頭頸部腫瘤患者的一級親屬應列為腫瘤易患高風險人群,加入五加皮髮揮瞭染色體穩定劑的作用,對博來黴素所緻的患者及一級親屬每細胞染色單體斷裂率有明顯的抑製作用.
배경:두경부종류여유전인소밀절상관,단기일급친속시부위종류고풍험인군?중약오가피유항돌변적염색체은정제,능부제고일급친속적항암능력?목적:탐토두경부종류적유전인소급오가피대기염색체적은정작용.설계:이인외주혈위대상적대조실험.단위:길림대학기출의학원의학유전학교연실급제일의원이비인후과,영국화위(옥서극)대학.대상:대상래원시간위2001-10/2002-03.두경종류환자급기일급친속균래자길림대학제일의원이비후과,건강인군래자장춘시중심혈참건강헌혈자.실험대상공110례,분위3조.①대조조50례,남25례,녀25례;래자건강헌혈자;균무암가족사,신체건강,무암증화병사.②환자조30례,남22례,녀8례;후암20례,비인암10례;미경방사치료급항종류약물치료.③일급친속조30례,남19례,녀11례;위후암、비인암환자적일급친속;제유암가족사외,신체건강.이상삼여자균지정동의.방법:채집실험대상외주혈,진행림파세포배양,배양주기위72 h,재67 h시가입치유변제박래매소(15 mg/L),항유변실험가입박래매소적동시가입오가피(800mg/L).계속배양72 h수획세포,상규방법제편,길모살불현대염색.선택분산호적분렬상,관찰염색체적단렬정황.계산평균매세포염색단체단렬솔(즉등우본조중소유염색단체단렬적총화제이소유관찰적세포총수).주요관찰지표:매세포염색단체단렬솔.결과:환자3조110례진입결과분석.①응용박래매소소치적매세포염색단체단렬솔:대조조명현저우환자조급일급친속조(0.16±0.06,0.48±0.14,0.42±0.12,P＜0.01),단환자조급일급친속조비교무차이(P＞0.05).②응용오가피화박래매소후여단순응용박래매소소치매세포염색단체단렬솔적비교:환자조급일급친속조균현저강저(0.48±0.14,0.15±0.08,0.42±0 12,0.17±0.11,P＜0 01).결론:두경부종류환자적일급친속응렬위종류역환고풍험인군,가입오가피발휘료염색체은정제적작용,대박래매소소치적환자급일급친속매세포염색단체단렬솔유명현적억제작용.
BACKGROUND: Cephalocervical cancer is closely related with genetic factors, but do the first-degree relatives have a higher risk for cancers? Slenderstyle acanthopanax root-bark has an anti-mutation chromosome stabilizer, can it enhance the anticaner ability of the first-degree relatives? OBJECTIVE: To study the genetic factor of cephalocervical cancer and antimutagenic effect of slenderstyle acanthopanax root-bark.DESIGN:A controlled experiment with human peripheral blood as the sample.SETTING: The Department of Medical Genetics of the Basic Medical Science School, and the Department of Otolaryngology of the First Hospital of Jilin University; The University of Warwick, UK.PARTICIPANTS: The subjects were taken during the period of October 2001 to March 2002. The patients with cephalocervical tumor and their first-degree relatives were all from the Department of Otolaryngology,FirstHospital of Jilin University, and healthy group were well-being blood devoting volunteers from Changchun City Central Blood Bank. There were group( n = 50) included 25 males and 25 females who were healthy blood patients group( n =30) were composed of 22 males and 8 females who did first-degree relative group(n=30) consisted of 19 males and 11 females. They were the first-degree relatives of patients with carcinoma of larynx and carcinoma of nasopharynx. Except for the family history of cancer,they themselves were all healthy. Informed consents were obtained from all of them.METHODS: The peripheral blood was collected as the sample and the lymphocyte culturing was performed. The culture cycle was 72 hours and bleomycin(BLM) (15 mL) was added into it at the 67~ hour, also the slenderstyle acanthopanax root-bark(SARB) (800 mg/L) was added into the antimutagenesis experiment. The cells were collected after culturing for another 72 hours. The conventional method was used for slide preparation. The slides were stained with Giemsa solution without banding. Choosing the proper objective and observing the numbers of chromatid breaks. The numbers of chromatid breaks were converted into the numbers of chromatid breaks per cell (b/c value). Namely, b/c value equals to the quotient, the number of chromatid break divided by the number of the cell observed in the slide.MAIN OUTCOME MEASURES: The number of chromatid breaks per cell (b/c value).RESULTS: All the 110 cases in the 3 groups entered the stage of result It was lower in the control group than that in the patients group and first-degree relatives group(0.16 ± 0.06, 0.48 ± 0. 14, 0.42 ± 0. 12, P ＜0.01). There was no significant difference in b/c value between the paparison between b/c value induced by combined SARB with BLM and only BLM was performed: The b/c value of former is significantly lower than the latter (0.48±0.14,0.15 ±0.08,0.42±0.12, 0.17±0.11,P ＜ 0.01).CONCLUSION: The first-degree relatives of the patients with cephalocervical cancers should be classified as tumor high-risk group. SARB as a chromatid stabilizer has an obvious inhibitory effect on b/c value of the patients induced by BLM and that of the first-degree relatives.